Literature DB >> 17534684

The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling.

Takao Ide1, Yoshihiko Kitajima, Atsushi Miyoshi, Takao Ohtsuka, Mayumi Mitsuno, Kazuma Ohtaka, Kohji Miyazaki.   

Abstract

BACKGROUND: Pancreatic cancer is one of the representative solid tumors, in which the hypoxic microenvironment plays a crucial role in malignant progression. We previously demonstrated that tumor-stromal interaction under hypoxia enhances the invasiveness of pancreatic cancer cells through hepatocyte growth factor (HGF)/c-Met signaling.
METHODS: We investigated the immunohistochemical expression of hypoxia inducible factor-1alpha (HIF-1alpha) c-Met, and HGF in both cancer and stromal cells using 41 pancreatic cancer tissue specimens, and tried to identify any correlations with the clinical features and survival.
RESULTS: Positive staining for HIF-1alpha was observed in both pancreatic cancer and the surrounding stromal cells in more than 30% of the cases, and it significantly correlated with lymph node metastasis (P < .05). A significant correlation was observed between the expression of HIF-1alpha and HGF in stromal cells (P < .05). In addition, the c-Met expression in cancer cells was found to significantly correlate with the HGF expression in not only cancer but also stromal cells. The disease-free survival rates of the patients with HIF-1alpha in cancer, stromal, c-Met in cancer, and an HGF expression in stromal cells was significantly worse than those without such expressions (P < .05).
CONCLUSIONS: These data suggest that the HGF/c-Met signaling via HIF-1alpha ?may therefore negatively affect the prognosis in patients with pancreatic cancer, and targeting tumor stroma under hypoxia might thus be potentially useful as a novel therapy for this cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534684     DOI: 10.1245/s10434-007-9435-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  41 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

Review 2.  c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Authors:  Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?

Authors:  Chen-Ting Lee; Thomas Mace; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 4.  Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies.

Authors:  Agnieszka Anna Rucki; Lei Zheng
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

5.  Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy.

Authors:  Kyle C Cuneo; Meredith A Morgan; Kent A Griffith; Peter G Hawkins; Joel K Greenson; Edgar Ben-Josef; Theodore S Lawrence; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-10-28       Impact factor: 7.038

6.  High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma.

Authors:  Lauren E Colbert; Sarah B Fisher; Serdar Balci; Burcu Saka; Zhengjia Chen; Sungjin Kim; Bassel F El-Rayes; N Volkan Adsay; Shishir K Maithel; Jerome C Landry; Walter J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-13       Impact factor: 7.038

7.  Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.

Authors:  Agnieszka A Rucki; Qian Xiao; Stephen Muth; Jianlin Chen; Xu Che; Jennifer Kleponis; Rajni Sharma; Robert A Anders; Elizabeth M Jaffee; Lei Zheng
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

8.  Adipocytes enhance murine pancreatic cancer growth via a hepatocyte growth factor (HGF)-mediated mechanism.

Authors:  Kathryn M Ziegler; Robert V Considine; Eben True; Deborah A Swartz-Basile; Henry A Pitt; Nicholas J Zyromski
Journal:  Int J Surg       Date:  2016-03-05       Impact factor: 6.071

9.  Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.

Authors:  Sergia Bortolanza; Maria Bunuales; Itziar Otano; Gloria Gonzalez-Aseguinolaza; Carlos Ortiz-de-Solorzano; Daniel Perez; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

10.  Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model.

Authors:  Dannel Yeo; Nhi Huynh; John A Beutler; Graham S Baldwin; Hong He; Mehrdad Nikfarjam
Journal:  J Invest Surg       Date:  2016-03-30       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.